Table 1.
Variables | Target |
Skeletal muscle biopsy | |
PGC-1α | |
Mitochondrial function in lateral vastus | O2 consumption |
Fatty acid transporter in the vastus lateralis and FAS (a key lipogenic enzyme) | |
IR β subunit in skeletal muscle (peripheral insulin sensitivity) | Metabolic |
Re-uptake of Ca2+ into the salcoplasmic reticulum | |
Physiological test | |
Exercise test | |
Improvement of ventilatory efficiency (increased value of PETCO2) | Respiratory function |
Oxygen consumption at the first ventilator threshold | Cardiac function |
Oxygen pulse | Cardiac function |
Parasympathetic activity (HR recovery) | Autonomic function |
Duration of exercise time | Autonomic function |
Distance walked during the 6-min walk | Work capacity |
Ultrasonography | |
Cardiac function | |
Reversed LV re-modelling (LV end diastolic and systolic volumes) | Cardiac function |
Ea | |
Diastolic function (e′, E, E/ e′, E/A ratio, higher proportion of e′ > 8 cm/s, E improvement during exercise), | |
Systolic function after 12 wk at rest and during exercise) | |
E reduction | |
Deceleration time increase | |
Left atrial volume | |
Reduced-plasma BNP | |
Vascular | |
Endothelial dysfunction (FMD) | Vascular function |
Coronary plaque necrotic core reduction in defined coronary segments | Vascular function |
Laboratory test | |
Myeloperoxidase | Anti-oxidant |
High sensitivity CRP | Inflammation |
Interleukin-6 | |
insulin sensitivity (HOMA index) | Metabolic |
HbA1C | |
Clinico-social data | |
Increased Short Form-36 physical/mental component scores and decreased Minnesota Living with Heart Failure questionnaire score | Quality of life |
Frequency of metabolic syndrome | Risk factor |
HOMA: Homoestasis model assessment; IR: Insulin receptor; PGC: Peroxisome-proliferator activated receptor γcoactivator; FMD: Flow mediated dilation; FAS: Fatty acid synthase; PETCO2: End-tidal carbon dioxide; HR: Heart rate; LV: Left ventricular; BNP: Brain natriuretic peptide.